Improved health status with SGLT2-inhibitor in HFrEF - PACE-CME

Improved health status with SGLTinhibitor in HFrEF

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

GLP-1RA treatment effect in patients with T2DM and PAD
GLP-1RA treatment effect in patients with T2DM and PAD
AHA 2019
GLP-1RA treatment effect in patients with T2DM and PAD
- Subodh Verma, MD, PhD
Possible favorable effects of icosapent ethyl on plaque-parameters
Possible favorable effects of icosapent ethyl on plaque-parameters
AHA 2019
Possible favorable effects of icosapent ethyl on plaque-parameters
- Prof. Stephen Nicholls
ARNI seems to give CV benefit not only in HFrEF, but up to EF of about 60%
ARNI seems to give CV benefit not only in HFrEF, but up to EF of about 60%
AHA 2019
ARNI seems to give CV benefit not only in HFrEF, but up to EF of about 60%
- Scott Solomon, MD
Is HF the same disease across the EF spectrum, or does HF have two physiologies that respond differently to treatment?
Is HF the same disease across the EF spectrum, or does HF have two physiologies that respond differently to treatment?
AHA 2019
Is HF the same disease across the EF spectrum, or does HF have two physiologies that respond differently to treatment?
- Prof. Lynne Stevenson